2018
Suppression of Ketogenesis in Type 1 Diabetes Is Not Delayed by SGLT2 Inhibitor Therapy
SIEBEL S, PATEL N, GALDERISI A, CARRIA L, TAMBORLANE W, SHERR J. Suppression of Ketogenesis in Type 1 Diabetes Is Not Delayed by SGLT2 Inhibitor Therapy. Diabetes 2018, 67 DOI: 10.2337/db18-117-lb.Peer-Reviewed Original ResearchPlasma glucoseSGLT2i useBHB levelsMedtronic MiniMedBoehringer Ingelheim GmbHSGLT2 inhibitor therapyInterruption studiesRapid-acting insulinType 1 diabetesRisk of DKABasal insulin infusionEli LillySuppression of ketogenesisCanagliflozin therapyRescue doseSGLT2i therapySGLT2i treatmentBasal insulinInhibitor therapySGLT2 inhibitorsT1D patientsAdjunctive agentsMetabolic decompensationInsulin infusionJanssen Pharmaceuticals
2016
Future Drug Treatments for Type 1 Diabetes
Sherr J, Cengiz E, Van Name M, Weinzimer S, Tamborlane W. Future Drug Treatments for Type 1 Diabetes. 2016, 985-999. DOI: 10.1002/9781118924853.ch66.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsInsulin analoguesDiabetes mellitusContinuous subcutaneous insulin infusion pumpType 2 diabetes mellitusType 1 diabetes mellitusInsulin deliveryBasal insulin analoguesNew treatment optionsFuture drug treatmentsAvailable insulin analoguesMore rapid absorptionClosed-loop deliveryDaily diabetes careAvailable insulin preparationsInsulin infusion pumpIntranasal glucagonInsulin therapyGlycemic controlAdjunctive agentsAvailable therapiesInjected medicationsDiabetes careTreatment optionsContinuous glucose monitorDrug treatment